title: Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: a small animal PET imaging study with 18F-FDG.
abstract: Cannabis use has been shown to alter brain metabolism in both rat models and humans although the observations between both species are conflicting. In the present study, we examined the short term effects of a single-dose injection of the synthetic cannabinoid agonist HU210 on glucose metabolism in the rat brain using small animal (18)F-2-fluoro-deoxyglucose (FDG) Positron Emission Tomography (PET) 15 min (Day 1) and 24h (Day 2) post-injection of the agonist in the same animal. Young adult male Wistar rats received an intra-peritoneal injection of HU210 (100 μg/kg, n=7) or vehicle (n=5) on Day 1. Approximately 1mCi of (18)F-FDG was injected intravenously into each animal at 15 min (Day 1) and 24h (Day 2) post-injection of HU210. A 5-min Computer Tomography (CT) scan followed by a 20-min PET scan was performed 40 min after each (18)F-FDG injection. Standardised Uptake Values (SUVs) were calculated for 10 brain regions of interest (ROIs). Global increased SUVs in the whole brain, hence global brain metabolism, were observed following HU210 treatment on Day 1 compared to the controls (21%, P<0.0001), but not in individual brain regions. On Day 2, however, no statistically significant differences were observed between the treated and control groups. At the 24h time point (Day 2), SUVs in the HU210 treated group returned to control levels (21-30% decrease compared to Day 1), in all ROIs investigated (P<0.0001). In the control group, SUVs did not differ between the two acquisition days in all brain regions. The present results suggest that high-dose HU210 increases brain glucose metabolism in the rat brain shortly after administration, in line with normalised human in vivo studies, an effect that was no longer apparent 24 h later.
authors.affiliation: ANSTO LifeSciences, Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW 2234, Australia. vhn@ansto.gov.au
authors.forename: Vu H
authors.initials: VH
authors.lastname: Nguyen
authors.forename: Mathieu
authors.initials: M
authors.lastname: Verdurand
authors.forename: Stefanie
authors.initials: S
authors.lastname: Dedeurwaerdere
authors.forename: Hongqin
authors.initials: H
authors.lastname: Wang
authors.forename: David
authors.initials: D
authors.lastname: Zahra
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Gregoire
authors.forename: Katerina
authors.initials: K
authors.lastname: Zavitsanou
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D001931:Brain Mapping; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D019788:Fluorodeoxyglucose F18; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D049268:Positron-Emission Tomography; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D018696:Neuroprotective Agents; D019788:Fluorodeoxyglucose F18; D013759:Dronabinol; C062018:HU 211